STAT3 and breast cancer: Combination therapy of sorafenib and SC-2001 (Mcl-1 inhibitor) inhibited STAT3 activation by RFX-dependent SHP-1 reactivation and defeated the sorafenib resistance in HCC and breast cancer cells [22,94,95].